# A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

> **NCT07703878** · PHASE1 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 302 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** GS-1206

## Key facts

- **NCT ID:** NCT07703878
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 302 (ESTIMATED)
- **Last updated:** 2026-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703878, "A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*